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Background: In the past, numerous studies revealed that supplementation with carnitine has multiple effects on
performance characteristics and gene expression in livestock and model animals. The molecular mechanisms
underlying these observations are still largely unknown. Increasing evidence suggests that microRNAs (miRNAs), a
class of small non-coding RNA molecules, play an important role in post-transcriptional regulation of gene expression
and thereby influencing several physiological and pathological processes. Based on these findings, the aim of the
present study was to investigate the influence of carnitine supplementation on the miRNA expression profile in
skeletal muscle of obese Zucker rats using miRNA microarray analysis.
Results: Obese Zucker rats supplemented with carnitine had higher concentrations of total carnitine in plasma and
muscle than obese control rats (P < 0.05). miRNA expression profiling in skeletal muscle revealed a subset of 152
miRNAs out of the total number of miRNAs analysed (259) were identified to be differentially regulated (adjusted
P-value < 0.05) by carnitine supplementation. Compared to the obese control group, 111 miRNAs were up-regulated
and 41 down-regulated by carnitine supplementation (adjusted P-value < 0.05). 14 of these miRNAs showed a log2
ratio≥ 0.5 and 7 miRNAs showed a log2 ratio≤ −0.5 (adjusted P-value < 0.05). After confirmation by qRT-PCR, 11
miRNAs were found to be up-regulated and 6 miRNAs were down-regulated by carnitine supplementation (P < 0.05).
Furthermore, a total of 1,446 target genes within the validated miRNAs were revealed using combined three
bioinformatic algorithms. Analysis of Gene Ontology (GO) categories and KEGG pathways of the predicted
targets revealed that carnitine supplementation regulates miRNAs that target a large set of genes involved in
protein-localization and -transport, regulation of transcription and RNA metabolic processes, as well as genes
involved in several signal transduction pathways, like ubiquitin-mediated proteolysis and longterm depression,
are targeted by the miRNAs regulated by carnitine supplementation.
Conclusion: The present study shows for the first time that supplementation of carnitine affects a large set of
miRNAs in skeletal muscle of obese Zucker rats suggesting a novel mechanism through which carnitine exerts its
multiple effects on gene expression, which were observed during the past.
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Carnitine is a metabolite which is best known for its role
as a shuttling molecule for the transport of long-chain
fatty acids from the cytosol into the mitochondrial
matrix where β-oxidation of fatty acids occurs [1]. Be-
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plementation with carnitine has positive effects on per-
formance characteristics (e.g. growth rate, reproductive
performance, protein:fat accretion) in livestock animals
[2-6]. In addition, convincing evidence has been pro-
vided that supplemental carnitine is useful for the treat-
ment of metabolic disorders that are associated with an
impaired glucose tolerance and/or insulin sensitivity like
diabetes and insulin resistance both, in model animals
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it has been shown that carnitine supplementation alters
the expression of a large number of genes involved in
important metabolic pathways, like glucose uptake and
oxidation, fatty acid oxidation and protein degradation
as well as critical signalling pathways, like the IGF-1/
PI3K/Akt pathway, in liver and/or skeletal muscle
[8-11], which may explain at least partially the above-
mentioned effects in livestock and model animals and
humans. However, the exact molecular mechanisms how
supplemental carnitine alters gene expression in tissues
are largely unknown.
Increasing evidence suggests that microRNAs (miRNAs),
a class of small non-coding RNA molecules (~22 nucleo-
tides), play an important role in post-transcriptional regula-
tion of gene expression and thereby influence a large
number of physiological processes including differentiation,
proliferation, apoptosis and immune response, but also
metabolic processes, like glucose and lipid metabolism
[12-14]. After maturation of the initially transcribed, so-
called primary miRNAs to the single-stranded mature form,
miRNAs are loaded into the RNA-induced silencing
complex (RISC), which subsequently interacts with the
miRNA recognition element (MRE) especially in the 3’
untranslated region (3’UTR) of the corresponding
mRNA (target mRNA) [13,15-17]. The kind of binding
and the involved proteins determine the further fate of
the target mRNAs, whose translation is either repressed
or which are degraded [18,19], thereby leading to down-
regulation of gene expression. Less commonly, miRNAs
can also up-regulate gene expression [20]. Noteworthy,
single miRNAs can regulate the expression of hundreds
of protein coding target mRNAs and, conversely, the ex-
pression of a single gene can be regulated by multiple
miRNAs, indicating the complexity of miRNA-mRNA
interrelationship and the great regulatory potential of
miRNAs [13,21,22].
Up to now, several experiments and clinical analysis
have been published demonstrating an altered miRNA
expression profile and a modified phenotype due to an
altered translation of target mRNAs in response to dif-
ferent pathologies [23-26] or pharmacologic treatment
[27]. In contrast, only few studies have evaluated the in-
fluence of dietary factors, such as high-cholesterol diet
[28] or conjugated linoleic acids [29], on the miRNA ex-
pression profile and its impact on gene expression in
model or livestock animals. In a recent study, we could
demonstrate that carnitine supplementation has benefi-
cial effects in obese Zucker rats [30] - an established
genetic model of obesity, metabolic syndrome and dia-
betes. The beneficial effect of carnitine supplementation
was evident by the observation that the obesity-induced
impairment of carnitine status and metabolic distur-
bances (mitochondrial dysfunction, impaired fatty acidoxidation, elevated plasma levels of triacylglycerides and
non-esterified fatty acids) were significantly improved or
even normalized [30]. The normalization of metabolic
disturbances in obese Zucker rats due to carnitine sup-
plementation was accompanied by an up-regulation of
genes involved in carnitine uptake, fatty acid transport
and uptake, β-oxidation, glucose uptake and glycolysis,
and a fiber switch from type II to type I in skeletal
muscle compared to non-supplemented Zucker rats
[30]. In light of the important role of miRNAs for regu-
lating gene expression, it is likely that at least some of
these profound changes in gene expression in obese
Zucker rats due to carnitine supplementation were me-
diated by altering miRNA expression in skeletal muscle.
To our knowledge it has not been studied yet whether
dietary carnitine influences miRNA expression. There-
fore, the aim of the present study was to investigate the
hypothesis that carnitine supplementation influences the
miRNA expression profile in skeletal muscle of obese
Zucker rats by using a miRNA microarray.
Results
Growth performance
Initial and final body weights after 28 days as well as daily
body weight gains did not differ between the obese control
group (367 ± 11, 507 ± 18, and 5.00 ± 0.54 g, respectively)
and the obese carnitine group (375 ± 18, 520 ± 19, and
5.18 ± 0.34 g, respectively) (mean ± SD, n = 6). Feed intake
and feed conversion ratio also did not differ between
the obese control group (25.6 ± 1.4 g/d and 5.14 ± 0.34 g
feed/g body weight gain, respectively) and the obese
carnitine group (26.4 ± 3.0 g/d and 5.12 ± 0.74 g feed/g
body weight gain) (mean ± SD, n = 6).
Carnitine concentrations in plasma and skeletal muscle
As shown in Figure 1, obese Zucker rats fed the diet
supplemented with carnitine had higher concentrations
of free-, acetyl- and total carnitine in plasma and skeletal
muscle than those of the control group (P < 0.05).
miRNA expression profiling in skeletal muscle of obese
Zucker rats
To investigate the effect of supplemental carnitine on
the muscle expression of miRNAs in obese Zucker rats,
we conducted miRNA microarray analysis using miR-
CURY LNA™ microRNA Array (7th Gen). According to
this miRNA profiling, 152 out of the total 259 miRNAs
analyzed were identified to be differentially regulated
(adjusted P-value < 0.05) by carnitine supplementation.
Compared to the obese control group, 111 miRNAs were
up-regulated and 41 down-regulated by carnitine supple-
mentation (adjusted P-value < 0.05). Group-specific signal
intensities are shown in Figure 2 and listed separately in
Additional file 1: Table S1 with log2 ratios and fold
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Figure 1 Concentrations of carnitine in plasma and skeletal muscle of obese Zucker rats. Concentrations of free, acetyl and total carnitine
in plasma (A) and skeletal muscle (B) of obese Zucker rats fed either a control diet (obese control) or a diet supplemented with carnitine (obese
carnitine). *Indicates significant difference from the obese control group (P < 0.05).
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Figure 2 Heat map and unsupervised hierarchical cluster
analysis of the differentially expressed miRNAs in skeletal
muscle of obese Zucker rats by supplemental carnitine. The
clustering was provided by Exiqon Services (Denmark) and carried
out using the complete-linkage method together with the euclidean
distance measure. Differentially expressed miRNAs chosen with an
adjusted P-value < 0.05. Each row represents an individual miRNA
and each column represents a sample. The miRNA clustering tree is
shown on the left. The color scale illustrates the relative expression
level of miRNAs. Red color represents an expression level below the
reference channel, and green color represents expression higher
than the reference. The codes on the legend are log2-transformed
values.
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and 7 miRNAs showed a log2 ratio ≤ −0.5 (adjusted P-
value < 0.05). A detailed list of these miRNAs and their
respective log2 ratios and fold changes as well as adjusted
P-values can be found in Table 1. The distribution of
group specific signal intensities of these 21 differentially
expressed miRNAs with adjusted P-value < 0.05 are shown
in Figure 3.
Validation of the most differentially expressed miRNAs by
qRT-PCR
To validate the microarray data, we performed qRT-PCR
to quantify the expression of the 21 most differentially
expressed miRNAs. As shown in Table 2, the expression
patterns of these miRNAs detected by qRT-PCR were
consistent with the microarray data. Among these 21
differentially expressed miRNAs, 17 (miR-10b-5p, miR-
223-3p, miR-208a-5p, miR-434-3p, miR-190a-5p, miR-
30d-5p, miR-347, miR-493-5p, miR-29a-5p, miR-451-5p,
miR-190b-5p, miR-466c-5p, miR-883-5p, miR-466b-1-
3p, miR-21-3p, miR-3596c, miR3584-3p) were proven
significant (P < 0.05) by qRT-PCR, one (miR-487b-3p)
had a tendency to be significant (P = 0.06), and three
(miR-138-2-3p, miR-1188-3p, miR-665) were not con-
firmed to be significant (Table 2). Only the 17 signifi-
cantly validated differentially expressed miRNAs, which
were proven significant by qRT-PCR, were used for the
subsequent target prediction and functional analysis.
Target prediction of the significantly validated
differentially expressed miRNAs and functional analysis
We performed target prediction for the 17 significantly
validated differentially expressed miRNAs (shown in
Table 2) to identify the influence of carnitine supple-
mentation on potential target mRNAs in skeletal muscle
of obese Zucker rats by combining the results from three
online free available algorithms. According to this, a
total of 868 and 578 target genes were identified for the
11 up-regulated and 6 down-regulated miRNAs, respect-
ively. Data are shown in Additional file 2: Table S2. To
elucidate the biological functions of the predicted targets
Table 1 Most strongly up-regulated (log2 Ratio ≥ 0.5) and
down-regulated (log2 Ratio ≤ −0.5) miRNAs in skeletal
muscle of Zucker rats by supplemental carnitine
ProbeID Annotation Log2 Ratio FC P-value*
Up-regulated miRNAs
148278 Rno-miR-138-2-3p 0.68 1.61 0.023
10925 Rno-miR-10b-5p 0.65 1.57 0.023
148261 Rno-miR-208a-5p 0.60 1.51 0.027
14285 Rno-miR-487b-3p 0.60 1.51 0.023
11024 Rno-miR-223-3p 0.59 1.51 0.023
11246 Rno-miR-434-3p 0.54 1.45 0.049
27536 Rno-miR-190a-5p 0.54 1.45 0.033
19596 Rno-miR-30d-5p 0.52 1.43 0.027
42763 Rno-miR-347 0.52 1.43 0.023
148059 Rno-miR-493-5p 0.51 1.43 0.023
145638 Rno-miR-29a-5p 0.51 1.43 0.023
42866 Rno-miR-451-5p 0.51 1.42 0.037
148417 Rno-miR-1188-3p 0.51 1.42 0.023
42472 Rno-miR-190b-5p 0.50 1.42 0.023
Down-regulated miRNAs
42586 Rno-miR-466c-5p −0.51 −1.42 0.023
42462 Rno-miR-883-5p −0.51 −1.43 0.023
148483 Rno-miR-466b-1-3p −0.55 −1.46 0.023
148583 Rno-miR-3584-3p −0.62 −1.54 0.041
42770 Rno-miR-665 −0.64 −1.55 0.027
148139 Rno-miR-3596c −0.73 −1.66 0.027
17896 Rno-miR-21-3p −0.78 −1.72 0.023
*P-values have been corrected for multiple testing by the Benjamini and
Hochberg adjustment method.
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Gene Ontology (GO) categories and Kyoto Encyclopedia
of Genes and Genomes (KEGG) pathway analysis by
using the DAVID Functional Annotation Chart tool sep-
arately for the targets identified for the 11 up- and 6
down-regulated miRNAs.
Gene-term enrichment analysis within GO category
“biological process” revealed that most target genes pre-
dicted from the 11 up-regulated miRNAs were involved
in protein localization, cell adhesion, biological adhesion,
protein transport and establishment of protein localization
(Figure 4, P < 0.01). In contrast, most target genes pre-
dicted from the 6 down-regulated miRNAs were involved
in “biological processes” dealing with regulation of tran-
scription, regulation of RNA metabolic process, as well as
regulation of transcription, DNA dependent (Figure 5,
P < 0.01). Within the GO category “molecular function”,
most of the target genes predicted from the 11 up-
regulated miRNAs were involved in enzyme- and RNA-
binding and in cytoskeletal protein binding (Figure 4,P < 0.01), while most of the targets from the 6 down-
regulated miRNAs had functions in ion-, metal ion- and
cation-binding, as well as nucleotide binding (Figure 5,
P < 0.01). Regarding the GO category “cell component”,
the greatest number of targets predicted from the 11
up-regulated miRNAs had functions associated with cell
projection (Figure 4, P < 0.01), whereas the functions of
the targets predicted from the 6 down-regulated miR-
NAs were associated with plasma membrane (Figure 5,
P < 0.01).
Gene-term enrichment analysis of the targets pre-
dicted from the significantly validated most differentially
expressed miRNAs using KEGG pathways revealed sev-
eral enriched regulatory pathways. As shown in Table 3,
enriched KEGG pathways (EASE score < 0.05) for the
868 putative mRNAs from the 11 up-regulated miRNAs
included pathways regulating cancer, the Wnt signalling
pathway, ubiquitin mediated proteolysis, leukocyte trans-
endothelial migration, adherens junction, longterm de-
pression and ether lipid metabolism, and for the 578
putative targets from the 6 down-regulated miRNAs path-
ways regulating ubiquitin mediated proteolysis, leukocyte
transendothelial migration, T cell receptor signalling and
long-term depression (Table 3).
Validation of selected predicted target genes by qRT-PCR
To explore whether the differentially expressed miR-
NAs were associated with changes in the mRNA levels
of respective target genes, we determined relative
mRNA levels of one selected potential target gene for
each validated miRNA by qRT-PCR. As shown in
Table 4, the relative mRNA levels of predicted targets
(UBE2A, HERC2, ARPC5, GNAI2, SLC6A8, IGF-1,
ITPR1, ACSL3, and SALL3) of 9 differentially regulated
miRNAs were significantly regulated by carnitine in the
opposite direction (P < 0.05), whereas the relative mRNA
levels of the predicted targets of the remaining differen-
tially regulated miRNAs were not significantly inversely
regulated.
IGF-1 protein level in skeletal muscle
To further investigate whether the carnitine-induced in-
crease in the mRNA level of IGF-1, a putative target
gene of miR-466b-1-3p but also miR-208a-5p, is also as-
sociated with an increase in the protein level of IGF-1,
we determined protein levels of IGF-1 in skeletal muscle
of the obese Zucker rats. Consistent with the higher
mRNA level of IGF-1, the relative protein level of IGF-1
was increased by 35% in the obese carnitine group com-
pared to the obese control group (Figure 6, P < 0.05).
Discussion
This is the first study demonstrating the response of the
miRNA expression profile to dietary supplementation
Figure 3 Heat map and unsupervised hierarchical cluster analysis of the most strongly differentially expressed miRNAs in skeletal
muscle of obese Zucker rats by supplemental carnitine. The clustering was provided by Exiqon Services (Denmark) and carried out using the
complete-linkage method together with the euclidean distance measure. Most strongly differentially expressed miRNAs chosen with a log2
Ratio≥ 0.5 and≤ −0.5 and an adjusted P-value < 0.05. Each row represents an individual miRNA and each column represents a sample. The miRNA
clustering tree is shown on the left. The color scale illustrates the relative expression level of miRNAs. Red color represents an expression level below
the reference channel, and green color represents expression higher than the reference. The codes on the legend are log2-transformed values.
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http://www.biomedcentral.com/1471-2164/15/512with carnitine. miRNAs represent a relatively newly identi-
fied class of small non-coding RNA molecules which play
an important role for gene expression by mainly down-
regulating the expression of protein-coding genes, and,
consequently influence both, physiological and pathological
processes. Since the molecular mechanisms underlying
changes in gene expression by carnitine supplementation in
livestock and model animals are only poorly understood,
the present study aimed to elucidate possible alterations in
the miRNA profile following dietary supplementation with
carnitine. For miRNA profiling, we used skeletal muscle
samples from carnitine-supplemented and control (non-
supplemented) obese Zucker rats, in which we have re-
cently reported profound changes in the expression of
genes involved in important metabolic pathways, like glu-
cose and fatty acid metabolism and protein degradation
[30]. It is well known that the carnitine status in obese
Zucker rats and other models of genetic and diet-induced
obesity is markedly impaired and as a consequence several
metabolic disturbances are induced [31-33]. In contrast,supplementation with carnitine improves carnitine status,
which was also demonstrated in the present study, and re-
verses to a great part these metabolic disturbances, like ele-
vated blood levels of triacylglycerides and non-esterified
fatty acids, glucose intolerance and insulin resistance
[30-32,34]. The key finding of the present study is that car-
nitine supplementation resulted in a profound change in
the miRNA expression profile in skeletal muscle of obese
Zucker rats suggesting a novel regulatory mechanism by
which dietary carnitine alters gene expression and mediates
at least some of its biological effects. According to our
miRNA microarray analysis, a total of 152 miRNAs were
identified to be differentially expressed, 111 being up-
regulated and 41 being down-regulated, in skeletal muscle
of the obese Zucker rats in response to carnitine supple-
mentation. In order to elucidate the functional implications
of alterations in the miRNA profile it is a widely accepted
approach to identify the miRNA target genes by employing
specific bioinformatics tools. Because one single miRNA
can regulate the expression of hundreds of target mRNAs,
Table 2 Validation of microarray results using qRT-PCR
Mean fold changes P-value*
miRNAs microarray qRT-PCR microarray qRT-PCR
miR-138-2-3p 1.61 1.07 0.023 0.676
miR-10b-5p 1.57 1.58 0.023 0.023
miR-487b-3p 1.51 1.26 0.023 0.060
miR-223-3p 1.51 1.59 0.023 0.015
miR-208a-5p 1.51 4.26 0.027 0.001
miR-434-3p 1.45 1.85 0.049 0.017
miR-190a-5p 1.45 1.50 0.033 0.016
miR-30d-5p 1.43 1.53 0.027 0.035
miR-347 1.43 1.52 0.023 0.048
miR-493-5p 1.43 1.64 0.023 0.001
miR-29a-5p 1.43 1.49 0.023 0.047
miR-451-5p 1.42 1.63 0.037 0.034
miR-1188-3p 1.42 1.12 0.023 0.500
miR-190b-5p 1.42 1.74 0.023 0.021
miR-466c-5p −1.42 −1.49 0.023 0.021
miR-883-5p −1.43 −2.28 0.023 0.005
miR-466b-1-3p −1.46 −1.76 0.023 0.011
miR-21-3p −1.72 −2.04 0.023 0.001
miR-3596c −1.66 −2.33 0.027 0.004
miR-665 −1.55 −1.22 0.027 0.140
miR-3584-3p −1.54 −2.78 0.041 0.003
*P-values have been corrected for multiple testing by the Benjamini and
Hochberg adjustment method.
Keller et al. BMC Genomics 2014, 15:512 Page 7 of 16
http://www.biomedcentral.com/1471-2164/15/512while one gene may be targeted by many miRNAs, target
prediction is usually carried out only in a small subset of
the differentially expressed miRNAs, typically in the most
strongly differentially regulated miRNAs. Following this ap-
proach, we selected those miRNAs, which were significantly
differentially expressed between the two groups at a log2
ratio of ≥ 0.5 and ≤ −0.5 according to microarray analysis
and according to qRT-PCR, resulting in 11 up-regulated
and 6 down-regulated miRNAs, respectively. The subse-
quent in silico-target mRNA prediction revealed 868 and
578 target genes for the 11 up-regulated and the 6 down-
regulated miRNAs, respectively. Due to the limited conclu-
siveness of in silico-predictions, we determined mRNA
levels of one individual target gene for each of the
carnitine-regulated miRNAs using qRT-PCR in order to
provide some proof of concept that predicted targets are in-
deed regulated in the expected direction in vivo. According
to this, we observed that the majority of predicted target
mRNAs of the differentially regulated miRNAs were regu-
lated by carnitine in the opposite direction indicating that
the predictions from in silico-analysis are reliable at least in
some instances. One of the predicted miRNA-mRNA inter-
actions, which could be confirmed in vivo, concerns theinsulin-like growth factor (IGF)-1. IGF-1 is a known target
of the down-regulated miR-466b-1-3p and has been dem-
onstrated to be up-regulated by carnitine in the present
study but also in previous studies [11,35]. In order to
strengthen the biological relevance of miRNA-mRNA inter-
actions for regulating gene expression by carnitine in the
case of IGF-1, we also determined protein levels of IGF-1.
In line with the elevated mRNA level of IGF-1 in skeletal
muscle, we also observed increased protein levels of IGF-1
in skeletal muscle of rats of the carnitine group. This sug-
gests that the elevated mRNA level of IGF-1 is a result of a
decreased repressive activity of the down-regulated miR-
466b-1-3p and that miRNA-mRNA interactions indeed
play a significant role in mediating biological effects of car-
nitine. One important reason that might explain that the
predictions of target mRNAs for differentially regulated
miRNAs are not reliable in all instances is that one gene is
normally subject to regulation by a cluster of miRNAs,
from which certain miRNAs can be regulated in the oppos-
ite direction. Another reason might be that the carnitine-
mediated change in the expression of certain miRNAs was
not strong enough to induce a significant change in the
expression of the targeted mRNAs. Moreover, post-
transcriptional modifications by carnitine might also be
responsible for the observation that predicted miRNA-
mRNA interactions are not visible in vivo. Finally, we
carried out gene-term enrichment analysis within the
three GO categories and the KEGG pathway database
using DAVID software, separately for the targets identified
from the prediction of the 11 up- and 6 down-regulated
miRNAs in order to identify biological functions of the
predicted targets.
Noteworthy, gene-term enrichment analysis of the tar-
gets predicted from the differentially regulated miRNAs
revealed that carnitine supplementation regulates miR-
NAs that target a large set of genes involved in enzyme-
and RNA-binding, regulation of transcription, regulation
of transcription-DNA dependent, regulation of RNA
metabolic process, and nucleotide-binding. This clearly
indicates that carnitine supplementation regulates many
genes which are involved in controlling gene expression
and that gene regulation by carnitine supplementation
is more complex due to miRNA-mRNA interactions
than previously thought. Amongst the predicted target
mRNAs of the regulated miRNAs we found about 60
mRNAs encoding transcription factors, which were clas-
sified according to their function into general and spe-
cific transcription factors (not shown). We found that
the main part belonged to the class specific transcription
factors, like ATF3, BCL6, BCOR, BHLHE23, BHLHE41,
CREM, E2F6, ELK4, HBP1, HIVEP1, IRF9, JUN, KLF15,
MEF2C and many others. These specific transcription
factors usually bind upstream of the initiation site to
specific recognition sequences of the regulated gene to
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Figure 4 Gene ontology analysis of the target genes of the validated 11 up-regulated miRNAs in skeletal muscle of Zucker rats with
P < 0.01. The GO terms were sorted by the number of genes in an ascending order from top to bottom.
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Figure 5 Gene ontology analysis of the target genes of the validated 6 down-regulated miRNAs in skeletal muscle of Zucker rats with
P < 0.01. The GO terms were sorted by the number of genes in an ascending order from top to bottom.
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Table 3 KEGG pathway analyses of the predicted target genes of the validated most differentially expressed
microRNAs with P < 0.05
Pathway P-value Genes
Putative targets of the up-regulated miRNAs
Athways in cancer 0.044 WNT5A, TCF7, FGFR3, RALBP1, VHL, TGFBR1, IGF1, CTNNA1, STK4,
ITGB1, IGF1R, CBLB, CCND1, HIF1A, CDKN1B, JUN, SOS2, HHIP, WNT9A, PIAS1
Wnt signalling pathway 0.012 WNT5A, TBL1XR1, TCF7, ROCK2, PPP2R5D, DKK2, CCND1, SIAH1A,
JUN, CAMK2B, WNT9A, PPP3CA, FBXW11
Ubiquitin mediated proteolysis 0.011 CUL3, UBE2N, UBE2A, CBLB, UBE3A, VHL, UBE2K, SIAH1A, UBE2I, HERC2, PIAS1, FBXW11
Leukocyte transendothelial migration 0.037 GNAI2, ACTN4, ROCK2, CXCR4, RAP1A, RAPGEF4, CTNNA1, ITGB1, CLDN23, PTPN11
Adherens junction 0.026 IGF1R, PVRL4, TCF7, TJP1, ACTN4, TGFBR1, CTNNA1, SNAI1
Longterm depression 0.048 IGF1R, GNAI2, PLA2G12A, GRID2, IGF1, PRKG2, ITPR2
Ether lipid metabolism 0.044 PLA2G12A, PLA2G7, PAFAH1B1, PPAP2A, PPAP2B
Putative targets of the down-regulated miRNAs
Ubiquitin mediated proteolysis 0.003 CUL3, UBE2N, UBE3A, VHL, RHOBTB2, BIRC6, UBA6, UBE2I, SMURF2, UBE2D1, CUL1
Leukocyte transendothelial migration 0.017 CLDN8, ITK, CLDN19, PIK3CA, RAPGEF4, CLDN11, ITGB1, MLLT4, PRKCB
T cell receptor signalling pathway 0.036 ITK, JUN, PIK3CA, CHP, DDAH1, NFATC3, LCP2, IL2
Long-term depression 0.042 GNAO1, IGF1, GUCY1B3, GRM1, ITPR1, PRKCB
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http://www.biomedcentral.com/1471-2164/15/512stimulate or repress its transcription. Although it is diffi-
cult to directly relate the functions of most these specific
transcription factors to recently observed carnitine ef-
fects in skeletal muscle, it is likely that carnitine medi-
ates at least some of its effects on gene expressionTable 4 Validation of predicted target-mRNAs using qRT-PCR
Predicted target mRNAs Related miRNA
Up-regulated miRNAs
WNT5A miR-10b-5p
UBE2A miR-223-3p
HERC2 miR-208a-5p
ALCAM miR-434-3p
ARPC5 miR-190a-5p
GNAI2 miR-30d-5p
FADS1 miR-347
PIAS1 miR-493-5p
CBLB miR-29a-5p
SAMD4B miR-451-5p
WSB1 miR-190b-5p
Down-regulated miRNAs
SLC6A8 miR-466c-5p
ABCG1 miR-883-5p
IGF-1 miR-466b-1-3p
ITPR1 miR-21-3p
ACSL3 miR-3596c
SALL3 miR-3584-3p
Data are expressed as means ± SD and were presented as fold of the obese control
difference to the obese control group (P < 0.05).through regulating transcription factor activities by
altering miRNA expression. The observation that the
minor part of the transcription factors targeted by the
carnitine-regulated miRNAs were general transcription
factors, like GTF2B, GTF2I, HMGB2, MED14, MED17,Obese control Obese carnitine
Fold of control
1.00 ± 0.57 0.80 ± 0.46
1.00 ± 0.48 0.52 ± 0.10*
1.00 ± 0.07 0.87 ± 0.08*
1.00 ± 0.13 0.97 ± 0.16
1.00 ± 0.18 0.73 ± 0.14*
1.00 ± 0.14 0.72 ± 0.07*
1.00 ± 0.44 0.86 ± 0.11
1.00 ± 0.50 1.02 ± 0.59
1.00 ± 0.46 0.91 ± 0.25
1.00 ± 0.38 0.98 ± 0.27
1.00 ± 0.41 0.67 ± 0.22
1.00 ± 0.44 2.34 ± 0.52*
1.00 ± 0.38 1.08 ± 0.26
1.00 ± 0.28 2.26 ± 0.65*
1.00 ± 0.29 1.37 ± 0.15*
1.00 ± 0.49 2.11 ± 0.87*
1.00 ± 0.44 6.32 ± 2.47*
group, which mean was set to 1; n = 6 rats/group. *Indicates significant
BA
*
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Figure 6 Relative protein level of IGF-1 in skeletal muscle of obese Zucker rats. (A) Representative immunoblots specific to IGF-1 and Vinculin
as internal control are shown for one animal per group; immunoblots for the other animals revealed similar results. (B) Bars represent data from
densitometric analysis and represent means ± SD (n = 6/group); bars are expressed relative to the protein level of the obese control group (=1.00).
*Indicates significant difference from the obese control group (P < 0.05).
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inducing carnitine effects in skeletal muscle [7], because
general transcription factors are essential for gene tran-
scription to occur due to their obligatory role in tran-
scription initiation by RNA polymerase II. Analysis of
the involvement of the predicted target genes in specific
KEGG pathways showed that particularly genes playing
roles in signal transduction pathways, like the Wnt sig-
nalling pathway (e.g. WNT5A, TBL1XR1, TCF7, JUN,
DKK2), long-term depression (e.g. IGF1, IGF1R, GNAI2
and PRKCB), and protein-degrading pathways, like
ubiquitin-mediated proteolysis (e.g. UBE2A, UBE3A,
VHL, UBA6, SMURF2), are targeted by the miRNAs
regulated by carnitine supplementation. Regulation of
miRNAs targeting genes belonging to ubiqutin-mediatedproteolysis may provide a plausible explanation for our
recent observations in rats and pigs that carnitine sup-
plementation down-regulates key genes involved in
ubiquitin-mediated proteolysis in skeletal muscle [9-11].
Ubiquitin-mediated proteolysis within proteasomes is
the most important protein degradation pathway in tis-
sues in general, and particularly responsible for the deg-
radation of myofibrillar proteins in skeletal muscle
which make up about 60% of total muscle proteins.
Thus, the observation that carnitine supplementation re-
duces muscle wasting in a rat model of cancer cachexia
[36], which is characterized by an increased activity of
ubiquitin-mediated proteolysis, is largely explained by
inhibition of this pathway. Inhibition of this pathway by
carnitine supplementation is probably mediated by
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been observed in several species including humans, pigs,
rats and chickens [35,37-41]. IFG-1 is an important
negative regulator of this protein degrading pathway and
this effect is mediated by an activation of the PI3/Akt
signalling pathway leading to inactivation of FoxO tran-
scription factors and thereby inhibition of the ubiquitin-
ligating E3 ligases [42]. Recently, we have indeed
observed that carnitine supplementation activates the
IGF-1/PI3K/Akt signalling pathway, inactivates FoxOs,
reduces expression of E3 ligases and decreases the
amount of ubiquitinated proteins which are targeted for
degradation via the proteasome [11]. Moreover, since
IGF-1 has also prominent functions in cell proliferation
and differentiation it was not surprising that enrichment
analysis identified IGF-1 as one gene involved in the
KEGG pathways “pathways in cancer” but also in “long-
term depression”, that was targeted by the miRNAs
down-regulated by carnitine supplementation. Thus, our
observations indicate that the recently observed in-
creases in mRNA and/or protein levels of IGF-1 follow-
ing carnitine supplementation is mediated at the level of
miRNA-mRNA interactions.
The large number of target genes (about 1,500) pre-
dicted from the most strongly regulated miRNAs and the
other not explicitly mentioned data from gene-term en-
richment analysis for the targets identified shows that car-
nitine supplementation may cause several other biological
effects than up-regulation of IGF-1 or inhibition of
ubiquitin-mediated proteolysis via miRNA-mRNA inter-
actions. However, the biological implications of most of
the observed carnitine-mediated changes in the miRNA
expression profile and its impact on specific metabolic
and signalling pathways and whole metabolism cannot be
resolved with certainty using biostatistics tools alone, be-
cause the prediction of target genes from differentially
expressed miRNAs is only an in silico-approach and, thus,
has clear limitations. Therefore, time-consuming experi-
mental studies with cultured muscle cells, in which the
effect of carnitine in the presence of miRNA-specific in-
hibitors or during over-expression or knockdown of spe-
cific miRNAs on target gene expression is studied, are
necessary in the future to validate at least some of the
carnitine-mediated miRNA-mRNA interactions. Given
that most of the detectable miRNAs (152 out of 259) were
regulated by carnitine, it would be interesting to investi-
gate in a future time-course experiment whether there are
early and late responding miRNAs which behave differ-
ently to carnitine supplementation.
Conclusions
The present study clearly shows for the first time that a
large set of miRNAs in skeletal muscle of obese Zucker
rats are responsive to carnitine supplementation suggestinga novel mechanism through which carnitine exerts its mul-
tiple effects on gene expression. Using biostatistics tools at
least some of the recently reported effects of carnitine
supplementation on gene expression (IGF-1, E3 ligases)
could be demonstrated to be likely mediated via miRNA-
mRNA interactions. Although the biological implications
of most of the observed carnitine-mediated changes in the
miRNA expression profile cannot be predicted using this
biostatistics approach alone and experimental validations
of miRNA-mRNA interactions are necessary, our results
indicate that carnitine supplementation exerts several
other biological effects through altering the expression of
miRNAs.
Methods
Animal experiment
The animal experiment was approved by the local Ani-
mal Care and Use Committee. For this study, we used
plasma and muscle samples from 6 obese Zucker rats
per group from a previous experiment [30]. In this ex-
periment, 8 to 10 week old, male obese (fa/fa) Zucker
rats (Crl:ZUC-Leprfa; Charles River, France) were ran-
domly divided in two groups (obese control group and
obese carnitine group) and fed semi-purified diets ac-
cording to the recommendations of the American Insti-
tute of Nutrition (AIN)-93G [43] ad libitum for 28 days.
The treatment duration was based on several reports in
the literature that carnitine supplementation improves
carnitine status and causes profound changes in gene ex-
pression in different tissues within a few weeks [7]. The
obese carnitine group received the same diet supple-
mented with 3 g carnitine/kg diet. Blood was collected
and plasma obtained by centrifugation, and skeletal
muscle (M. rectus femoris) was excised and immediately
stored at −80°C. A detailed description of the animal ex-
periment and sample collection can be found in our
previous publication [30].
Carnitine analysis
Concentrations of free carnitine and acetyl carnitine in
plasma and muscle were determined by tandem mass
spectrometry using deuterated carnitine-d3 as internal
standard as described recently in detail [44]. Concentra-
tion of total carnitine was calculated as the sum of free
and acetyl carnitine.
RNA isolation
For miRNA microarray and qRT-PCR analysis total
RNA, including small RNAs, was isolated from muscle
samples using the Qiagen miRNeasy Mini Kit (Qiagen,
Hilden, Germany), according to the manufacturer’s
protocol. Afterwards, the concentration of the RNA was
determined using an Infinite 200 M microplate reader
and a nanoQuant Plate (both from Tecan, Männedorf,
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gel electrophoresis. Isolated RNA samples were immedi-
ately frozen and stored at −80°C.
miRNA microarray analysis
All microarray analyses were conducted at Exiqon Ser-
vices (Denmark). Sample total RNA quality was verified
using an Agilent BioAnalyzer 2100 System. MiRCURY
LNA™ microRNA Arrays (7th Gen) following the miR-
BASE release 18 (http://www.mirbase.org/) were used to
analyze the expression profile of each sample (Exiqon,
Denmark). Briefly, 750 ng total RNA from both sample
and reference was labeled using the mercury LNA™
microRNA Hi-Power Labeling Kit, Hy3™/Hy5™ (Exiqon,
Denmark) and were mixed pair-wise and hybridized ac-
cording to the instruction manual using a Tecan
HS4800™ hybridization station (Tecan, Austria). After-
wards, slides were scanned using the Agilent G2565BA
Microarray scanner System (Agilent Technologies, Inc.,
USA) and image analysis was carried out using the Ima-
Gene® 9 (mercury LNA™ microRNA Array Analysis Soft-
ware, Exiqon, Denmark). The quantified signals were
background corrected (Normexp with offset value 10,
see [45]) and normalized using the global Lowess (LO-
cally WEighted Scatterplot Smoothing) regression algo-
rithm. The signal values were filtered based on absent/
present calls. miRNAs with present calls < 20% were re-
moved from the final dataset used for the expression
analysis. The microarray data related to all samples have
been deposited in NCBI’s Gene Expression Omnibus
public repository [46].
qRT-PCR validation of differentially expressed miRNAs
qRT-PCR reactions were performed using a Rotor-Gene
2000 system (Corbett Research, Mortlake, Australia) to
validate the expression of 21 miRNAs, which showed
significant differences in their expression level with an
adjusted P < 0.05 in the microarray experiment. For this
end, 0.5 μg of total RNA (RNA templates were the same
as used for microarray hybridizations) were reverse tran-
scribed using the miScript II RT Kit (Qiagen, Hilden,
Germany), according the manufacturer’s protocol and
was stored in diluted (1:10) aliquots at −20°C. 2 μl
cDNA, 2 μl each of miScript Universal Primer (10x) and
miScript Primer Assay (10x) and 4 μl RNase free water
were added to 10 μl QuantiTect SYBR Green PCR Mas-
ter Mix (2x) (all from Qiagen, Hilden, Germany). The
qRT-PCR cycle comprised of, 15-minute incubation at
95°C followed by 40 cycles of a three-stage temperature
profile of 94°C for 15 sec and 55°C for 30 sec and final
70°C for 30 sec. The relative changes of each transcript
were calculated by using the the 2-ΔCt equation [47] with
the expression level of U6 snRNA (U6 small nuclear
RNA) as an internal control.Prediction of targets of differentially expressed
microRNAs and functional analysis
Prediction of putative miRNA targets was performed by
using three online free available algorithms TargetScan
release version 6.2 (http://www.targetscan.org/), miRanda
and miRDB (http://mirdb.org/miRDB/). To identify
enriched (overrepresented) Gene Ontology (GO) terms
and Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways for the target genes of the differentially
expressed miRNAs, we used the Database for Annota-
tion, Visualization and Integrated Discovery (DAVID)
gene annotation tool [48].
qRT-PCR validation of selected potential target genes
qRT-PCR analysis of predicted target genes and refer-
ence genes as well as calculation of gene expression data
was performed as described recently in detail [10]. The
normalization factor was calculated as the geometric
mean of expression data of the three most stable out of
six tested potential reference genes (CANX, MDH1,
ACTB, RPL13, TOP1, and ATP5B). The three most stable
reference genes were (the stability score M as calculated
by GeNorm is shown in brackets): CANX (0.025), TOP1
(0.030) and RPL13 (0.036). Means and SD were calculated
from normalized expression data for samples of the same
treatment group. The mean of the obese control group
was set to 1 and mean and SD of the obese carnitine
group were scaled proportionally. Features of gene-
specific primer pairs are listed in Table 5.
Western Blotting
For western blot analysis, frozen muscle samples (30 mg)
were homogenized in RIPA buffer (radioimmunoprecipi-
tation assay buffer; 50 mM Tris, 150 mM NaCl, 10% gly-
cerol, 0.1% SDS, 1% Triton X-100, 1 mM EDTA, 0.5%
deoxycholate, 1% protease inhibitor mix; pH 7.5) using
an Ultraturrax (IKA Werke GmbH, Staufen, Germany).
The homogenate was centrifuged at 16,200 g (4°C) for
15 min. Protein concentrations were determined in the
supernatants using the bicinchoninic acid protein assay
kit (Interchim, Montluçon, France) with BSA as stand-
ard. Subsequently, equal amounts (50 μg) of protein
samples were separated on 12.5% SDS-PAGE and electro-
transferred to a nitrocellulose membrane (Pall Corpor-
ation, Pensacola, FL, USA). Loading of equal amounts of
protein in each line was verified by Ponceau S (Carl Roth,
Karlsruhe, Germany) staining. After incubation the mem-
branes overnight at 4°C in blocking solution (5% nonfat
dried milk powder), membranes were incubated with pri-
mary antibodies against IGF-1 (polyclonal anti-IGF-1 anti-
body; Santa Cruz Biotechnology, Inc., Santa Cruz, Ca,
USA) and Vinculin (monoclonal anti-Vinculin antibody;
Invitrogen Corporation, CA, USA) as a reference protein
for normalization. The membranes were washed, and then
Table 5 Characteristics of specific primers used for validation of target-mRNAs by qRT-PCR
Gene Forward Primer (3’-5’) Reverse Primer (3’-5’) Product length (bp) Tm (°C) NCBI GenBank
Reference genes
ACTB GACCTCTATGCCAACACAGT CACCAATCCACACAGAGTAC 154 60 NM_031144.2
ATP5B GCACCGTCAGAACTATTGCT GAATTCAGGAGCCTCAGCAT 203 60 NM_134364.1
CANX CCAGATGCAGATCTGAAGAC CTGGGTCCTCAATTTCACGT 175 60 NM_172008.2
MDH1 CAGACAAAGAAGAGGTTGCC CGTCAGGCAGTTTGTATTGG 206 60 NM_033235.1
RPL13 CTTAAATTGGCCACGCAGCT CTTCTCAACGTCTTGCTCTG 198 60 NM_031101.1
TOP1 GAAGAACGCTATCCAGAAGG GCTTTGGGACTCAGCTTCAT 137 60 NM_022615.1
Target genes
ABCG1 GCCATCCCTGTCTTGCTCTT TCCTCTCGGTCCAAGCCATA 143 56 NM_053502.1
ACSL3 GTAAAACTTGATTCCCGTTGAGA GTGTCGCAGCCAGGATACA 307 60 NM_057107.1
ALCAM TCGCTGACCCTCATCGTAGA ATCGTCTGCCTCATCGTGTT 321 60 NM_031753.1
ARPC5 GGGATGTCGAAGAACACGGT GTAGGCATGAGTCCACCTCG 142 60 NM_001025717.1
CBLB TTGAAGGGTGAAGATGCTTTTGAT ACTGGAGCCTGGAGGTTTTG 105 60 NM_133601.1
FADS1 CCACTACGCTGGTCAGGATG AGCGCCTTATTCTTGGTGGG 144 60 NM_053445.2
GNAI2 GCCGAGCGCTCTAAGATGAT TGCTTGACGATGGTGCTCTT 119 60 NM_031035.3
HERC2 CCTGACCACCGAGAGGAAAC ACACCATCATCTGGATATCTGTT 102 60 NM_001107520.1
IGF-1 CCCGGGACGTACCAAAATGAGCG ATGTCAGTGTGGCGCTGGGC 354 64 NM_001082477.2
ITPR1 ATGCCAGGAGGAAATGCGAA CTCAGGGGTGGACTTGGTTC 250 60 NM_006236992.1
PIAS1 ATGACCTGCTGGACGAACTG ACTGTCGTGGACAATCGGAC 355 60 NM_001106829.2
SALL3 CTCTTCTTGGTTTCCTAGGCGT TCCGCCCACTTGAAGAACTC 130 60 NM_001108892.1
SAMD4B TGTGGACCTCCCCTGCTTTG GAGCAAAGGCACAGAAACCTG 199 60 NM_001107498.1
SLC6A8 GGTCCCCTGTCATCGAGTTC GAGGACCACGTAGGGGAATG 197 60 NM_017348.2
UBE2A TGTGGAAACCACAGGACAACT CAGTCACGCCAGCTTTGTTC 327 60 NM_001013933.1
WNT5A TCCGCAGTCCTGCTTTGAAT CAAAGCCACTCCTGGGCTTA 156 60 NM_022631.1
WSB1 GAGTTCCCGGAATCAGACGG CCGGAGCAAAAGCAACAGTC 163 60 NM_00104256.1
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ondary polyclonal anti-rabbit-IgG antibody (Sigma-
Aldrich, Steinheim, Germany) at RT. Afterwards blots
were developed using ECL Plus or ECL Advanced (both
GE Healthcare, Munich, Germany). The signal intensities
of specific bands were detected with a Bio-Imaging system
(Syngene, Cambridge, UK) and quantified using Syngene
GeneTools software (nonlinear dynamics).
Statistical analysis
Values presented in the text are means ± SD. Data were
analyzed by Student’s t test with dietary carnitine con-
centration as factor using the Minitab statistical software
(Release 13, Minitab Inc., State College, PA, USA).
Means were considered significantly different at P < 0.05.
P-values of microarray data have been corrected for
multiple testing by the Benjamini and Hochberg adjust-
ment method. miRNAs with an adjusted P-value < 0.05
were considered to be differentially expressed miRNAs
by carnitine supplementation. Subsequently, genes found
to be significant by the one-way ANOVA test have beensubjected to the Tukey's ‘Honest Significant Difference’
test to determine which groups contribute most to the
significant difference.
Availability of supporting data
The microarray data set supporting the results of this art-
icle is available in the Gene Expression Omnibus reposi-
tory, GEO Series accession number GSE58537, http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE58537.Additional files
Additional file 1: Differentially expressed miRNAs by supplemental
carnitine in skeletal muscle of obese Zucker rats. Spreadsheet contains all
differentially expressed miRNAs by carnitine with an adjusted P-value < 0.05.
Additional file 2: Predicted target genes of the 17 validated, most
differentially expressed miRNAs by supplemental carnitine in
skeletal muscle of obese Zucker rats. Spreadsheet contains target genes
of the validated 11 up- and 6 down-regulated miRNAs by supplemental
carnitine predicted by at least one and a maximum of three online free
available algorithms TargetScan, miRanda and miRDB.
Keller et al. BMC Genomics 2014, 15:512 Page 15 of 16
http://www.biomedcentral.com/1471-2164/15/512Abbreviations
miRNA: microRNA; qRT-PCR: Quantitative real time-polymerase chain reaction;
IGF-1: Insulin like growth factor 1; GO: Gene ontology; KEGG: Kyoto
encyclopedia of genes and genomes.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JK and KE designed research and coordinated the study. JK carried out the
molecular biological analyses. JK, RR and KE wrote the paper. All authors
read and approved the final manuscript.
Acknowledgements
Janine Keller is financed by the Deutsche Forschungsgemeinschaft (DFG;
Germany). The authors are very grateful to Erika Most for carnitine analytics.
Received: 12 November 2013 Accepted: 17 June 2014
Published: 21 June 2014
References
1. Kerner J, Hoppel C: Fatty acid import into mitochondria. Biochim Biophys
Acta 2000, 1486:1–17.
2. Owen KQ, Nelssen JL, Goodband RD, Weeden TL, Blum SA: Effect of
L-carnitine and soybean oil on growth performance and body
composition of early-weaned pigs. J Anim Sci 1996, 74:1612–1619.
3. Musser RE, Goodband RD, Tokach MD, Owen KQ, Nelssen JL, Blum SA, Dritz
SS, Civis CA: Effects of L-carnitine fed during gestation and lactation on
sow and litter performance. J Anim Sci 1999, 77:3289–3295.
4. Heo K, Odle J, Han IK, Cho W, Seo S, van Heugten E, Pilkington DH: Dietary
L-carnitine improves nitrogen utilization in growing pigs fed low energy,
fat-containing diets. J Nutr 2000, 130:1809–1814.
5. Eder K, Ramanau A, Kluge H: Effect of L-carnitine supplementation on
performance parameters in gilts and sows. J Anim Physiol Anim Nutr (Berl)
2001, 85:73–80.
6. Ramanau A, Kluge H, Spilke J, Eder K: Reproductive performance of sows
supplemented with dietary L-carnitine over three reproductive cycles.
Arch Tierernahr 2002, 56:287–296.
7. Ringseis R, Keller J, Eder K: Role of carnitine in the regulation of glucose
homeostasis and insulin sensitivity: evidence from in vivo and in vitro
studies with carnitine supplementation and carnitine deficiency.
Eur J Nutr 2012, 51:1–18.
8. Keller J, Ringseis R, Priebe S, Guthke R, Kluge H, Eder K: Effect of L-carnitine
on the hepatic transcript profile in piglets as animal model. Nutr Metab
(Lond) 2011, 8:76.
9. Keller J, Ringseis R, Priebe S, Guthke R, Kluge H, Eder K: Dietary L-carnitine
alters gene expression in skeletal muscle of piglets. Mol Nutr Food Res
2011, 55:419–429.
10. Keller J, Ringseis R, Koc A, Lukas I, Kluge H, Eder K: Supplementation with
l-carnitine downregulates genes of the ubiquitin proteasome system in
the skeletal muscle and liver of piglets. Animal 2012, 6:70–78.
11. Keller J, Couturier A, Haferkamp M, Most E, Eder K: Supplementation of
carnitine leads to an activation of the IGF-1/PI3K/Akt signalling path
way and down regulates the E3 ligase MuRF1 in skeletal muscle of rats.
Nutr Metab (Lond) 2013, 10:28.
12. Ambros V: The functions of animal microRNAs. Nature 2004, 431:350–355.
13. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell 2004, 2004(116):281–297.
14. Qin W, Shi Y, Zhao B, Yao C, Jin L, Ma J, Jin Y: miR-24 regulates apoptosis
by targeting the open reading frame (ORF) region of FAF1 in cancer
cells. PLoS One 2010, 5:e9429.
15. Shivdasani RA: MicroRNAs: regulators of gene expression and cell
differentiation. Blood 2006, 108:3646–3653.
16. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP:
MicroRNA targeting specificity in mammals: determinants beyond seed
pairing. Mol Cell 2007, 27:91–105.
17. Filipowicz W, Bhattacharyya SN, Sonenberg N: Mechanisms of post-
transcriptional regulation by microRNAs: are the answers in sight?
Nat Rev Genet 2008, 9:102–114.
18. Wienholds E, Plasterk RH: MicroRNA function in animal development.
FEBS Lett 2005, 579:5911–5922.19. Wu L, Fan J, Belasco JG: MicroRNAs direct rapid deadenylation of mRNA.
Proc Natl Acad Sci U S A 2006, 103:4034–4039.
20. Ørom UA, Nielsen FC, Lund AH: MicroRNA-10a binds the 5’UTR of
ribosomal protein mRNAs and enhances their translation. Mol Cell 2008,
30:460–471.
21. Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P,
da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N: Combinatorial microRNA
target predictions. Nat Genet 2005, 37:495–500.
22. Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by
adenosines, indicates that thousands of human genes are microRNA
targets. Cell 2005, 120:15–20.
23. Cheng Y, Ji R, Yue J, Yang J, Liu X, Chen H, Dean DB, Zhang C: MicroRNAs
are aberrantly expressed in hypertrophic heart: do they play a role in
cardiac hypertrophy? Am J Pathol 2007, 170:1831–1840.
24. Ikeda S, Kong SW, Lu J, Bisping E, Zhang H, Allen PD, Golub TR, Pieske B,
Pu WT: Altered microRNA expression in human heart disease.
Physiol Genomics 2007, 31:367–373.
25. Zhang B, Pan X, Cobb GP, Anderson TA: microRNAs as oncogenes and
tumor suppressors. Dev Biol 2007, 302:1–12.
26. Yildirim SS, Akman D, Catalucci D, Turan B: Relationship between
downregulation of miRNAs and increase of oxidative stress in the
development of diabetic cardiac dysfunction: junctin as a target protein
of miR-1. Cell Biochem Biophys 2013, 67:1397–1408.
27. Shen H, Liu T, Fu L, Zhao S, Fan B, Cao J, Li X: Identification of microRNAs
involved in dexamethasone-induced muscle atrophy. Mol Cell Biochem
2013, 381:105–113.
28. Karere GM, Glenn JP, VandeBerg JL, Cox LA: Differential microRNA
response to a high-cholesterol, high-fat diet in livers of low and high
LDL-C baboons. BMC Genomics 2012, 13:320.
29. Parra P, Serra F, Palou A: Expression of adipose microRNAs is sensitive to
dietary conjugated linoleic acid treatment in mice. PLoS One 2010, 5:e13005.
30. Couturier A, Ringseis R, Mooren FC, Krüger K, Most E, Eder K: Carnitine
supplementation to obese Zucker rats prevents obesity-induced type II
to type I muscle fiber transition and favors an oxidative phenotype of
skeletal muscle. Nutr Metab (Lond) 2013, 10:48.
31. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O, Bain J,
Stevens R, Dyck JR, Newgard CB, Lopaschuk GD, Muoio DM: Mitochondrial
overload and incomplete fatty acid oxidation contribute to skeletal
muscle insulin resistance. Cell Metab 2008, 7:45–56.
32. Noland RC, Koves TR, Seiler SE, Lum H, Lust RM, Ilkayeva O, Stevens RD,
Hegardt FG, Muoio DM: Carnitine insufficiency caused by aging and
overnutrition compromises mitochondrial performance and metabolic
control. J Biol Chem 2009, 284:22840–22852.
33. Ringseis R, Mooren FC, Keller J, Couturier A, Wen G, Hirche F, Stangl GI, Eder
K, Krüger K: Regular endurance exercise improves the diminished hepatic
carnitine status in mice fed a high-fat diet. Mol Nutr Food Res 2011,
55(Suppl 2):193–202.
34. Power RA, Hulver MW, Zhang JY, Dubois J, Marchand RM, Ilkayeva O, Muoio
DM, Mynatt RL: Carnitine revisited: potential use as adjunctive treatment
in diabetes. Diabetologia 2007, 50:824–832.
35. Heo YR, Kang CW, Cha YS: L-Carnitine changes the levels of insulin-like
growth factors (IGFs) and IGF binding proteins in streptozotocin-induced
diabetic rat. J Nutr Sci Vitaminol (Tokyo) 2001, 47:329–334.
36. Busquets S, Serpe R, Toledo M, Betancourt A, Marmonti E, Orpí M, Pin F,
Capdevila E, Madeddu C, López-Soriano FJ, Mantovani G, Macciò A, Argilés
JM: L-Carnitine: an adequate supplement for a multi-targeted anti-
wasting therapy in cancer. Clin Nutr 2012, 31:889–895.
37. Di Marzio L, Moretti S, D'Alò S, Zazzeroni F, Marcellini S, Smacchia C, Alesse
E, Cifone MG, De Simone C: Acetyl-L-carnitine administration increases
insulin-like growth factor 1 levels in asymptomatic HIV-1-infected
subjects: correlation with its suppressive effect on lymphocyte apoptosis
and ceramide generation. Clin Immunol 1999, 92:103–110.
38. Kita K, Kato S, Amanyaman M, Okumura J, Yokota H: Dietary L-carnitine
increases plasma insulin-like growth factor-I concentration in chicks fed
a diet with adequate dietary protein level. Br Poult Sci 2002, 43:117–121.
39. Doberenz J, Birkenfeld C, Kluge H, Eder K: Effects of L-carnitine
supplementation in pregnant sows on plasma concentrations of
insulin-like growth factors, various hormones and metabolites and
chorion characteristics. J Anim Physiol Anim Nutr (Berl) 2006, 90:487–499.
40. Woodworth JC, Tokach MD, Nelssen JL, Goodband RD, Dritz SS, Koo SI,
Minton JE, Owen KQ: Influence of dietary L-carnitine and chromium
Keller et al. BMC Genomics 2014, 15:512 Page 16 of 16
http://www.biomedcentral.com/1471-2164/15/512picolinate on blood hormones and metabolites of gestating sows fed
one meal per day. J Anim Sci 2007, 85:2524–2537.
41. Brown KR, Goodband RD, Tokach MD, Dritz SS, Nelssen JL, Minton JE,
Higgins JJ, Lin X, Odle J, Woodworth JC, Johnson BJ: Effects of feeding
L-carnitine to gilts through day 70 of gestation on litter traits and
the expression of insulin-like growth factor system components and
L-carnitine concentration in foetal tissues. J Anim Physiol Anim Nutr (Berl)
2008, 92:660–667.
42. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden
KC, Blenis J, Greenberg ME: Akt promotes cell survival by phosphorylating
and inhibiting a Forkhead transcription factor. Cell 1999, 96:857–868.
43. Reeves PG, Nielsen FH, Fahey GC: AIN-93 purified diets for laboratory
rodents: final report of the American Institute of Nutrition ad hoc writing
committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993,
123:1939–1951.
44. Hirche F, Fischer M, Keller J, Eder K: Determination of carnitine, its
short chain acyl esters and metabolic precursors trimethyllysine and
gamma-butyrobetaine by quasi-solid phase extraction and MS/MS
detection. J Chromatogr B Analyt Technol Biomed Life Sci 2009,
877:2158–2162.
45. Ritchie ME, Silver J, Oshlack A, Holmes M, Diyagama D, Holloway A,
Smyth GK: A comparison of background correction methods for
two-colour microarrays. Bioinformatics 2007, 23:2700–2707.
46. Edgar R, Domrachev M, Lash AE: Gene Expression Omnibus: NCBI gene
expression and hybridization array data repository. Nucleic Acids Res 2002,
30:207–210.
47. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using
real-time quantitative PCR and the 2(−Delta Delta C(T)) Method.
Methods 2001, 25:402–408.
48. da Huang W, Sherman BT, Lempicki RA: Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources.
Nat Protoc 2009, 4:44–57.
doi:10.1186/1471-2164-15-512
Cite this article as: Keller et al.: Supplemental carnitine affects the
microRNA expression profile in skeletal muscle of obese Zucker rats.
BMC Genomics 2014 15:512.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
